Related Experiment Video
Updated: Jul 4, 2026

Single-stage Dynamic Reanimation of the Smile in Irreversible Facial Paralysis by Free Functional Muscle Transfer
Published on: March 1, 2015
Botulinum Toxin Type A as an Early Intervention for Traumatic Oculomotor Nerve Palsy: A Pediatric Case Report
Chihiro Koiwa1, Takashi Negishi2, Megumi Ito3
1Department of Ophthalmology, Faculty of Medicine, Juntendo University, Tokyo, JPN.
Insights
Early botulinum toxin type A (BTX-A) injection effectively treated traumatic third cranial nerve palsy in a pediatric patient. This minimally invasive approach prevented muscle contracture and promoted significant functional recovery, offering a promising therapeutic option.
Area of Science:
- Ophthalmology
- Neurology
- Trauma Surgery
Background:
- Traumatic third cranial nerve palsy is a rare but severe complication of head injury with a poor prognosis.
- Conventional conservative management often leads to unsatisfactory functional outcomes.
Abstract:
Traumatic third cranial nerve palsy is a rare complication of head injury, with an incidence of approximately 1% and a characteristically poor prognosis. Conventional management remains conservative, often yielding unsatisfactory outcomes. We report the case of a 13-year-old girl who developed complete right third cranial nerve palsy following a 15-meter fall, presenting with exotropia (35Δ), ptosis, complete ophthalmoplegia, and pupillary dysfunction. Brain CT revealed hemorrhage in the right cavernous sinus, and subsequent MRI demonstrated focal nerve damage. Thirty-eight days post-injury, a single botulinum toxin type A (BTX-A) injection (5 units) was administered to the right lateral rectus muscle. Progressive improvement in ocular alignment and motility was observed, with resolution of diplopia by 4.5 months and sustained orthotropia at 10 months post-injury. Although pupillary dilation persisted, functional recovery was substantial. This case demonstrates that early BTX-A intervention may prevent lateral rectus contracture and promote functional recovery in traumatic third cranial nerve palsy. BTX-A represents a promising minimally invasive therapeutic option that warrants further investigation in larger patient populations.
Related Concept Videos
Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin
The binding of dantrolene to the RYR1...
Botulism

